News

Thornton & Ross News

STADA invests $660 Million USD in Takeda’s OTC portfolio in Russia/CIS to become a major player in these branded markets

  • • STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries


  • • The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl


  • • Peter Goldschmidt, CEO of STADA, comments: “This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market.“

Bad Vilbel, Moscow, November 5, 2019 – STADA Arzneimittel AG (together with its subsidiaries ‘STADA’ or ‘the Group’) has agreed to acquire a portfolio of selected products from Takeda Pharmaceutical Company Limited for a total value of $660 Million USD. The portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan will be divested to STADA Arzneimittel AG.

The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl, a well-known name and category leader in Russia, which is used to prevent blood clots, as well as the newer, patent-protected Nesina (for type II diabetes treatment) and Edarbi (angiotensin II receptor blocker for blood pressure control).

The acquired portfolio complements STADA’s existing portfolio and capabilities in Russia which include medicines from 16 of 20 therapeutic groups of the best-selling products in retail pharmacies. The transaction will enable the Group to continue expanding its consumer health business in Russia and the CIS. It is expected that the highly capable approximately 500-strong sales and marketing team from Takeda’s business will transfer to STADA on completion of the transaction, which is expected in the first quarter of 2020. In addition, Takeda and STADA will enter into manufacturing and supply agreements in connection with the acquisition under which Takeda will continue to supply the products to STADA. The acquisition is expected to be financed by new debt financing.

Peter Goldschmidt, CEO of STADA, commented: “This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market. This transaction also reflects the ambitions of STADA as we continue expanding the business internationally – both organically and through acquisitions – and continue generating significant operating efficiencies worldwide. STADA’s branded products are already well-represented in the most popular pharmacy categories in our key markets. However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments.”

Advisers to STADA on this transaction included: Nomura (M&A) and Kirkland & Ellis LLP (legal).

News

STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business

The STADA Group continues its growth trajectory in Europe. The company, announced that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.

Click for more info

Is veganism good for your health?

The Future of Your Health report indicates that nearly a third of Brits don’t think so

Click for more info

ALVOTECH AND STADA AGREE ON STRATEGIC BIOSIMILAR PARTNERSHIP

Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG ("STADA") today announced that they have entered into an exclusive strategic partnership for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Click for more info

STADA invests $660 Million USD in Takeda's OTC portfolio in Russia/CIS to become a major player in these branded markets

STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries

Click for more info

STADA to acquire Walmark - a leading Consumer Healthcare company in Central Europe

STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Click for more info

Q&A 2019 Pharmacy Show

A Q&A Session with Phoebe Buckley on the 2019 Pharmacy Show

Click for more info

STADA Health Report 2019

More than half of people in UK are optimistic about the future of health

Click for more info

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

>> News Archive